Patent US6682520B2 successfully refreshed from Google Patents.
US6682520B2
Expired / Lapsed
US
⏱️ 0.0 years remaining
Tissue volume reduction
Assignee: Pulmonx Corp
•
Filing: 2001-04-20
•
Granted: 2004-01-27
•
Expires: 2021-04-20
Abstract
Abstract Devices, compositions, and methods for achieving non-surgical lung volume reduction (e.g., bronchoscopic lung volume reduction (BLVR)) are described. BLVR can be carried out by collapsing a region of the lung, adhering one portion of the collapsed region to another, and promoting fibrosis in or around the adherent tissue.
Inventors
- 👤 Edward P. Ingenito
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 08:19
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/36; A61K38/363; A61B; A61B17/00; A61B17/00491; A61B17/12; A61B17/12022; A61B17/12099; A61B17/12104; A61B17/12131; A61B17/12136; A61B17/12181; A61B17/12186; A61K38/18; A61K38/1825; A61K38/1841; A61K38/1858; A61K38/43; A61K38/46; A61K38/48; A61K38/482; A61K38/4833; A61K45/00; A61K45/06; A61P; A61P11/00; A61B1/00; A61B1/267; A61B1/2676; A61B2017/00495
Claims Analysis
Total Claims: 35
Claim 1
Independent Claim
77 words
A method of reducing lung volume in a patient, the method comprising: (a) advancing a bronchoscope into a region of the lung targeted for reduction; and (b) introducing biological or biochemical material into the targeted region through the bronchoscope to reduce the volume of the targeted region by inducing collapse of the targeted region; promoting adhesion between one portion of the collapsed lung and another; and promoting fibrosis in or around the collapsed region of the lung.
Claim 2
Independent Claim
77 words
A method of reducing lung volume in a patient, the method comprising: (a) advancing a bronchoscope into a region of the lung targeted for reduction; and (b) introducing biological or biochemical material into the targeted region through the bronchoscope to reduce the volume of the targeted region by inducing collapse of the targeted region; promoting adhesion between one portion of the collapsed lung and another; and promoting fibrosis in or around the collapsed region of the lung.
Claim 3
Dependent Claim
16 words
The method of claim 1 , wherein the biological or biochemical material comprises fibrin or fibrinogen.
Claim 4
Dependent Claim
18 words
The method of claim 2 , wherein the biological or biochemical material further comprises a polypeptide growth factor.
Claim 5
Dependent Claim
24 words
The method of claim 3 , wherein the polypeptide growth factor is a fibroblast growth factor or a transforming growth factor beta-like (TGFβ-like) polypeptide.
Claim 6
Dependent Claim
34 words
The method of claim 1 , wherein the biological or biochemical material comprises fibrinogen and promoting adhesion between one portion of the collapsed lung and another is facilitated by administration of a fibrinogen activator.
Claim 7
Dependent Claim
12 words
The method of claim 5 , wherein the fibrinogen activator is thrombin.
Claim 8
Dependent Claim
12 words
The method of claim 2 , wherein the fibrinogen comprises 3-12% fibrinogen.
Claim 9
Dependent Claim
13 words
The method of claim 7 , wherein the fibrinogen comprises approximately 10% fibrinogen.
Claim 10
Dependent Claim
26 words
The method of claim 1 , wherein promoting fibrosis in or around the collapsed region of the lung is achieved by administering a polypeptide growth factor.
Claim 11
Dependent Claim
17 words
The method of claim 9 , wherein the polypeptide growth factor is a fibroblast growth factor (FGF).
Claim 12
Dependent Claim
15 words
The method of claim 10 , wherein the FGF is basic fibroblast growth factor (bFGF).
Claim 13
Dependent Claim
16 words
The method of claim 9 , wherein the polypeptide growth factor is transforming growth factor-beta (TGF-β).
Claim 14
Dependent Claim
22 words
The method of claim 1 , further comprising, prior to collapsing a region of the lung, inflating the region with absorbable gas.
Claim 15
Independent Claim
75 words
A method for reducing lung volume in a patient, the method comprising (a) advancing a bronchoscope into a region of the lung targeted for reduction; and (b) introducing biological or biochemical material into the targeted region through the bronchoscope to reduce the volume of the targeted region, wherein the biological or biochemical material introduced through the bronchoscope induces collapse of the targeted region; and promotes adhesion between one collapsed portion of the lung and another.
Claim 16
Independent Claim
75 words
A method for reducing lung volume in a patient, the method comprising (a) advancing a bronchoscope into a region of the lung targeted for reduction; and (b) introducing biological or biochemical material into the targeted region through the bronchoscope to reduce the volume of the targeted region, wherein the biological or biochemical material introduced through the bronchoscope induces collapse of the targeted region; and promotes adhesion between one collapsed portion of the lung and another.
Claim 17
Dependent Claim
24 words
The method of claim 14 , wherein the biological or biochemical material further promotes fibrosis in or around the collapsed region of the lung.
Claim 18
Dependent Claim
16 words
The method of claim 14 , wherein the biological or biochemical material comprises fibrin or fibrinogen.
Claim 19
Dependent Claim
18 words
The method of claim 14 , wherein the biological or biochemical material further comprises a polypeptide growth factor.
Claim 20
Dependent Claim
24 words
The method of claim 17 , wherein the polypeptide growth factor is a fibroblast growth factor or a transforming growth factor beta-like (TGFβ-like) polypeptide.
Claim 21
Dependent Claim
27 words
The method of claim 14 , wherein the biological or biochemical material is fibrinogen and the method further comprises introducing a fibrinogen activator into the targeted region.
Claim 22
Dependent Claim
12 words
The method of claim 19 , wherein the fibrinogen activator is thrombin.
Claim 23
Dependent Claim
24 words
The method of claim 14 , wherein the biological or biochemical material is fibrinogen, the fibrinogen being administered in a formulation containing 3-12% fibrinogen.
Claim 24
Dependent Claim
13 words
The method of claim 21 , wherein the formulation comprises approximately 10% fibrinogen.
Claim 25
Dependent Claim
18 words
The method of claim 14 , further comprising reducing the risk of infection by administration of an antibiotic.
Claim 26
Dependent Claim
18 words
The method of claim 23 , wherein the antibiotic is administered together with the biological or biochemical material.
Claim 27
Dependent Claim
61 words
A non-surgical method for performing lung volume reduction, the method comprising: (a) collapsing a region of the lung; (b) adhering one portion of the collapsed region to another; and (c) promoting fibrosis in or around the collapsed region of the lung, wherein promoting fibrosis in or around the collapsed region of the lung is achieved by administering a polypeptide growth factor.
Claim 28
Dependent Claim
61 words
A non-surgical method for performing lung volume reduction, the method comprising: (a) collapsing a region of the lung; (b) adhering one portion of the collapsed region to another; and (c) promoting fibrosis in or around the collapsed region of the lung, wherein promoting fibrosis in or around the collapsed region of the lung is achieved by administering a polypeptide growth factor.
Claim 29
Dependent Claim
17 words
The method of claim 25 , wherein the polypeptide growth factor is a fibroblast growth factor (FGF).
Claim 30
Dependent Claim
15 words
The method of claim 25 , wherein the FGF is basic fibroblast growth factor (bFGF).
Claim 31
Dependent Claim
16 words
The method of claim 25 , wherein the polypeptide growth factor is transforming growth factor-beta (TGF-β).
Claim 32
Dependent Claim
18 words
The method of claim 25 , further comprising reducing the risk of infection by administration of an antibiotic.
Claim 33
Dependent Claim
19 words
The method of claim 29 , wherein the antibiotic is administered together with fibrinogen, fibrin, or a fibrinogen activator.
Claim 34
Dependent Claim
22 words
The method of claim 25 , further comprising, prior to collapsing a region of the lung, inflating the region with absorbable gas.
Claim 35
Dependent Claim
16 words
The new method of claim 31 , wherein the absorbable gas is at least 90% oxygen.
References Cited (Backward Citations)
EP0303756A2
Cited
US4886496A
Cited
US6117425A
Cited
US5690675A
Cited
US5739288A
Cited
US5773418A
Cited
WO1995013748A1
Cited
US5437292A
Cited
US5836905A
Cited
US5583114A
Cited
US5733545A
Cited
US5814022A
Cited
US5980866A
Cited
WO1997033633A1
Cited
US5728132A
Cited
WO1999025782A2
Cited
US6174323B1
Cited
WO2001002042A1
Cited
US6287290B1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2007-01-26 | 2007-07-28 | 2008-01-27 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2011-01-26 | 2011-07-28 | 2012-01-27 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2015-01-26 | 2015-07-28 | 2016-01-27 | $7700.00 | Window Closed / Lapsed |